• (PLX AI) – Centene has signed a definitive agreement to sell Magellan Rx to Prime Therapeutics LLC (Prime) and a separate definitive agreement to sell PANTHERx Rare to a consortium of The Vistria Group, General Atlantic, and Nautic Partners.
  • • Centene intends to use the majority of the net proceeds from the sales to repurchase stock and the balance to reduce debt
  • • Each of the transactions is expected to be neutral to slightly accretive to Centene's Adjusted Earnings Per Share in the 12-month period post-closing

Quelle: PLX AI